ClinicalTrials.gov recorded primary completion on 2026-06-17 for Plozasiran in a phase 3 study of adults with severe hypertriglyceridemia. The trial, listed as NCT06347016, enrolled 311 participants and compared plozasiran injection with placebo.
Background
The study focused on severe hypertriglyceridemia, with the posted record describing evaluation of the safety and efficacy of plozasiran injection, also listed as ARO-APOC3, in adult participants. The trial status is ACTIVE_NOT_RECRUITING.
Trial design
According to the study record, eligible participants were randomized to receive 4 doses of plozasiran or placebo, given once every 3 months. Participants were to be evaluated for efficacy and safety, and after Month 12 eligible participants could enter an optional open-label extension under a separate protocol.
What this means
Primary completion means the trial reached the planned timepoint for its main outcomes, but the ClinicalTrials.gov entry does not provide posted results here. For clinicians, researchers, and patient advocates, the completion milestone signals that data review and reporting may follow for a large 311-participant phase 3 study in a population with severe hypertriglyceridemia.
Source
This information is based on ClinicalTrials.gov for NCT06347016, a trial record updated on 2026-06-17. The record is available at clinicaltrials.gov.